456 related articles for article (PubMed ID: 30857876)
1. Prognostic impact of celiac lymph node involvement in patients after frontline treatment for advanced ovarian cancer.
Angeles MA; Ferron G; Cabarrou B; Balague G; Martínez-Gómez C; Gladieff L; Pomel C; Martinez A
Eur J Surg Oncol; 2019 Aug; 45(8):1410-1416. PubMed ID: 30857876
[TBL] [Abstract][Full Text] [Related]
2. Celiac lymph node resection and porta hepatis disease resection in advanced or recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Martinez A; Pomel C; Mery E; Querleu D; Gladieff L; Ferron G
Gynecol Oncol; 2011 May; 121(2):258-63. PubMed ID: 21295334
[TBL] [Abstract][Full Text] [Related]
3. Cardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study.
Lopes A; Rangel Costa RL; di Paula R; Anton C; Calheiros Y; Sartorelli V; Kanashiro YM; de Lima JA; Yamada A; Pinto GLS; Vianna MR; Nogueira Dias Genta ML; Ribeiro U; Dos Santos MO
Int J Gynecol Cancer; 2019 Jan; 29(1):188-194. PubMed ID: 30640703
[TBL] [Abstract][Full Text] [Related]
4. Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer.
Cowan RA; Tseng J; Murthy V; Srivastava R; Long Roche KC; Zivanovic O; Gardner GJ; Chi DS; Park BJ; Sonoda Y
Gynecol Oncol; 2017 Nov; 147(2):262-266. PubMed ID: 28888540
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic value of selective lymphadenectomy in interval debulking surgery for stage IIIc and IV epithelial ovarian cancer.
Song N; Gao Y
Int J Gynecol Cancer; 2019 May; 29(4):761-767. PubMed ID: 30850437
[TBL] [Abstract][Full Text] [Related]
6. What can we learn from the 10 mm lymph node size cut-off on the CT in advanced ovarian cancer at the time of interval debulking surgery?
Benoit L; Zerbib J; Koual M; Nguyen-Xuan HT; Delanoy N; Le Frère-Belda MA; Bentivegna E; Bats AS; Fournier L; Azaïs H
Gynecol Oncol; 2021 Sep; 162(3):667-673. PubMed ID: 34217542
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of mesenteric lymph nodes involvement in patients undergoing posterior pelvic exenteration during radical or supra-radical surgery for advanced ovarian cancer.
Berretta R; Capozzi VA; Sozzi G; Volpi L; Ceni V; Melpignano M; Giordano G; Marchesi F; Monica M; Di Serio M; Riccò M; Ceccaroni M
Arch Gynecol Obstet; 2018 Apr; 297(4):997-1004. PubMed ID: 29380107
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group.
Vincent L; Jankowski C; Ouldamer L; Ballester M; Bendifallah S; Bolze PA; Akladios C; Costaz H; Lavoué V; Canlorbe G; Collinet P; Touboul C; Huchon C; Bricou A; Dridi S; Padéano MM; Bengrine L; Arnould L; Coutant C;
Eur J Surg Oncol; 2020 Sep; 46(9):1689-1696. PubMed ID: 32417154
[TBL] [Abstract][Full Text] [Related]
9. Hepatoceliac Lymph Node Involvement in Advanced Ovarian Cancer Patients: Prognostic Role and Clinical Considerations.
Gallotta V; Ferrandina G; Vizzielli G; Conte C; Lucidi A; Costantini B; De Rose AM; Di Giorgio A; Zannoni GF; Fagotti A; Scambia G; Chiantera V
Ann Surg Oncol; 2017 Oct; 24(11):3413-3421. PubMed ID: 28718034
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors for and prognostic value of mesenteric lymph node involvement in advanced-stage ovarian cancer.
Gouy S; Goetgheluck J; Uzan C; Duclos J; Duvillard P; Morice P
Eur J Surg Oncol; 2012 Feb; 38(2):170-5. PubMed ID: 22104389
[TBL] [Abstract][Full Text] [Related]
11. Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.
Tang J; Liu DL; Shu S; Tian WJ; Liu Y; Zang RY
Eur J Surg Oncol; 2013 Jul; 39(7):786-91. PubMed ID: 23490332
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors and the role of primary debulking in operable stage IVB ovarian cancer with supraclavicular lymph node metastasis: a retrospective study in Chinese patients.
Quan C; Chen X; Wen H; Wu X; Li J
BMC Cancer; 2024 May; 24(1):565. PubMed ID: 38711015
[TBL] [Abstract][Full Text] [Related]
13. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of supradiaphragmatic lymphadenopathy identified on preoperative computed tomography scan in patients undergoing primary cytoreduction for advanced epithelial ovarian cancer.
Kolev V; Mironov S; Mironov O; Ishill N; Moskowitz CS; Gardner GJ; Levine DA; Hricak H; Barakat RR; Chi DS
Int J Gynecol Cancer; 2010 Aug; 20(6):979-84. PubMed ID: 20683405
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of pelvic and para-aortic lymphadenectomy on clinically-apparent stage I primary mucinous epithelial ovarian carcinoma: a multi-institutional study with propensity score-weighted analysis.
Yoshihara M; Kajiyama H; Tamauchi S; Iyoshi S; Yokoi A; Suzuki S; Kawai M; Nagasaka T; Takahashi K; Matsui S; Kikkawa F
Jpn J Clin Oncol; 2020 Feb; 50(2):145-151. PubMed ID: 31688935
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Factors Affecting Lymph Node Metastasis in Clinical Stage I-II Epithelial Ovarian Cancer.
Erdem B; Yüksel IT; Peker N; Ulukent SC; Aşıcıoğlu O; Özaydin IY; Ülker V; Akbayir O
Oncol Res Treat; 2018; 41(7-8):444-448. PubMed ID: 29975960
[TBL] [Abstract][Full Text] [Related]
17. Oncologic outcomes in patients undergoing maximal or optimal cytoreductive surgery for Stage 3C serous ovarian, tubal or peritoneal carcinomas.
Gurkan D; Ceren Akin A; Sahin H; Aytac Tohma Y; Sahin EA; Gunakan E; Iflazoglu N; Nihan Haberal A; Ayhan A
J Obstet Gynaecol; 2020 May; 40(4):551-557. PubMed ID: 31482736
[TBL] [Abstract][Full Text] [Related]
18. Isolated lymph node recurrence in epithelial ovarian cancer: Recurrence with better prognosis?
Delangle R; Rossard L; Cirier J; Delvallée J; Bendifallah S; Touboul C; Collinet P; Coutant C; Akladios C; Lavoué V; Bolze PA; Huchon C; Bricou A; Canlorbe G; Ballester M; Darai E; Body G; Ouldamer L;
Eur J Obstet Gynecol Reprod Biol; 2020 Jun; 249():64-69. PubMed ID: 32381349
[TBL] [Abstract][Full Text] [Related]
19. Outcome of surgery in advanced ovarian cancer varies between geographical regions; opportunities for improvement in The Netherlands.
Timmermans M; Sonke GS; Slangen BFM; Baalbergen A; Bekkers RLM; Fons G; Gerestein CG; Kruse AJ; Roes EM; Zusterzeel PLM; Van de Vijver KK; Kruitwagen RFPM; van der Aa MA
Eur J Surg Oncol; 2019 Aug; 45(8):1425-1431. PubMed ID: 31027945
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of celiac lymph node involvement in ovarian cancer.
Martínez A; Pomel C; Filleron T; De Cuypere M; Mery E; Querleu D; Gladieff L; Poilblanc M; Ferron G
Int J Gynecol Cancer; 2014 Jan; 24(1):48-53. PubMed ID: 24356411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
